Abstract | AIM: METHODS: Transcriptome sequencing was performed on NPC biopsy samples from 12 pairs of patients with different metastasis risks. Bioinformatics and qPCR were used to identify differentially expressed genes (DEGs), while univariate and multivariate analyses were used to select prognostic indicators for the gene signature. A signature-based nomogram was established in a training cohort (n = 191) and validated in an external cohort (n = 263). RESULTS: Eleven DEGs were identified between metastatic and non-metastatic NPC. Four of these (AK4, CPAMD8, DDAH1 and CRTR1) were used to create a gene signature that effectively categorised patients into low- and high-risk metastasis groups (training: 91.1 versus 70.4%, p < 0.0001, C-index = 0.752; validation: 88.4 versus 73.9%, p = 0.00057, C-index = 0.741). IC with concurrent chemoradiotherapy (CCRT) improved distant metastasis-free survival in low-risk patients (94.4 versus 85.0%, p = 0.043), whereas patients in the high-risk group did not benefit from IC (72.6 versus 74.9%, p = 0.946). CONCLUSIONS: Our transcriptomics-based gene signature was able to reliably predict metastasis in locoregionally advanced NPC and could be used to identify candidates that could benefit from IC + CCRT.
|
Authors | Sai-Lan Liu, Xue-Song Sun, Qiu-Yan Chen, Ze-Xian Liu, Li-Juan Bian, Li Yuan, Bei-Bei Xiao, Zi-Jian Lu, Xiao-Yun Li, Jin-Jie Yan, Shu-Mei Yan, Jian-Ming Li, Jin-Xin Bei, Hai-Qiang Mai, Lin-Quan Tang |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 163
Pg. 26-34
(03 2022)
ISSN: 1879-0852 [Electronic] England |
PMID | 35032814
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Topics |
- Chemoradiotherapy
- Humans
- Induction Chemotherapy
- Nasopharyngeal Carcinoma
(drug therapy)
- Nasopharyngeal Neoplasms
(drug therapy, genetics)
- Transcriptome
|